Table 1 Patient characteristics
From: A multigene array for measurable residual disease detection in AML patients undergoing SCT
All AML patients with pre-SCT samples available (n=74) | |
Age: median | 38 (range 12–72) |
Sex | 54% female |
Pathological diagnosis at time of allo-SCT | |
CR1 | 32% |
CR2 | 30% |
⩾CR3 | 3% |
Active | 35% |
Three-year outcomes following allo-SCT | |
Alive | 36% |
Dead—relapse | 34% |
Dead—non-relapse | 30% |
Median survival post allo-SCT | 343 days (range: 6–7000 days) |
